Original Article | Published:

Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa

Gene Therapy volume 23, pages 196204 (2016) | Download Citation

Abstract

The X-linked RP3 gene codes for the ciliary protein RPGR and accounts for over 10% of inherited retinal degenerations. The critical RPGR-ORF15 splice variant contains a highly repetitive purine-rich linker region that renders it unstable and difficult to adapt for gene therapy. To test the hypothesis that the precise length of the linker region is not critical for function, we evaluated whether adeno-associated virus-mediated replacement gene therapy with a human ORF15 variant containing in-frame shortening of the linker region could reconstitute RPGR function in vivo. We delivered human RPGR-ORF15 replacement genes with deletion of most (314 codons, ‘short form’) or 1/3 (126 codons, ‘long form’) of the linker region to Rpgr null mice. Human RPGR-ORF15 expression was detected post treatment with both forms of ORF15 transgenes. However, only the long form correctly localized to the connecting cilia and led to significant functional and morphological rescue of rods and cones. Thus the highly repetitive region of RPGR is functionally important but that moderate shortening of its length, which confers the advantage of added stability, preserves its function. These findings provide a theoretical basis for optimizing replacement gene design in clinical trials for X-linked RP3.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. X-linked retinitis pigmentosa: RPGR mutations in most families with definite X linkage and clustering of mutations in a short sequence stretch of exon ORF15. Invest Ophthalmol Vis Sci 2003; 44: 1458–1463.

  2. 2.

    , , , , , et al. Comprehensive survey of mutations in RP2 and RPGR in patients affected with distinct retinal dystrophies: genotype-phenotype correlations and impact on genetic counseling. Hum Mutat 2007; 28: 81–91.

  3. 3.

    , , , , , et al. Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci 2012; 53: 8232–8237.

  4. 4.

    , , , , , et al. Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2013; 54: 1411–1416.

  5. 5.

    , , , , , . A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc Natl Acad Sci USA 2000; 97: 3649–3654.

  6. 6.

    , , , , . Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Invest Ophthalmol Vis Sci 2007; 48: 1298–1304.

  7. 7.

    , , , , , et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet 2000; 25: 462–466.

  8. 8.

    , , , , , et al. RPGR isoforms in photoreceptor connecting cilia and the transitional zone of motile cilia. Invest Ophthalmol Vis Sci 2003; 44: 2413–2421.

  9. 9.

    , . Mutations of RPGR in X-linked retinitis pigmentosa (RP3). Hum Mutat 2002; 19: 486–500.

  10. 10.

    , , , , , et al. A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. Am J Hum Genet 2002; 70: 1545–1554.

  11. 11.

    , , , , , . and RPGR mutations and clinical correlations in patients with X-linked retinitis pigmentosa. Am J Hum Genet 2003; 73: 1131–1146.

  12. 12.

    , . Identification of a novel protein interacting with RPGR. Hum Mol Genet 2000; 9: 2085–2093.

  13. 13.

    , , , , , et al. The retinitis pigmentosa GTPase regulator (RPGR) interacts with novel transport-like proteins in the outer segments of rod photoreceptors. Hum Mol Genet 2000; 9: 2095–2105.

  14. 14.

    , , , . Retinitis pigmentosa GTPase regulator (RPGR)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. J Biol Chem 2001; 276: 12091–12099.

  15. 15.

    , . Complex expression pattern of RPGR reveals a role for purine-rich exonic splicing enhancers. Invest Ophthalmol Vis Sci 2002; 43: 3373–3382.

  16. 16.

    , , , , , et al. Cone versus rod disease in a mutant Rpgr mouse caused by different genetic backgrounds. Invest Ophthalmol Vis Sci 2010; 51: 1106–1115.

  17. 17.

    , , , , , et al. RPGR-associated retinal degeneration in human X-linked RP and a murine model. Invest Ophthalmol Vis Sci 2012; 53: 5594–5608.

  18. 18.

    , , , , , et al. Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15. PLoS One 2012; 7: e35865.

  19. 19.

    , , , , . A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo. Invest Ophthalmol Vis Sci 2005; 46: 435–441.

  20. 20.

    , , , , . Mutational risk in highly repetitive exon ORF15 of the RPGR multidisease gene is not associated with haplotype background. Int J Mol Med 2005; 16: 1175–1178.

  21. 21.

    , , , , . Population haplotypes of exon ORF15 of the retinitis pigmentosa GTPase regulator gene in Germany: implications for screening for inherited retinal disorders. Mol Diagn Ther 2006; 10: 115–123.

  22. 22.

    , , , , , et al. AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci 2007; 48: 3954–3961.

  23. 23.

    , , , , , . Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Therapy 2010; 17: 117–131.

  24. 24.

    , , , , , et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007; 81: 11372–11380.

  25. 25.

    , , , , , et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Therapy 2008; 15: 463–467.

  26. 26.

    , , , , , . Rootletin, a novel coiled-coil protein, is a structural component of the ciliary rootlet. J Cell Biol 2002; 159: 431–440.

  27. 27.

    , , , , , et al. X-linked cone-rod dystrophy (locus COD1): identification of mutations in RPGR exon ORF15. Am J Hum Genet 2002; 70: 1049–1053.

  28. 28.

    , , , , , et al. Mutations in the RPGR gene cause X-linked cone dystrophy. Hum Mol Genet 2002; 11: 605–611.

  29. 29.

    , , , . The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1996; 37: 1693–1698.

  30. 30.

    , , , , , et al. AAV-mediated gene therapy in mouse models of recessive retinal degeneration. Curr Mol Med 2012; 12: 316–330.

  31. 31.

    , , , , , et al. Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis. Hum Gene Ther 2010; 21: 993–1004.

  32. 32.

    , , , , , et al. Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 2005; 46: 3039–3045.

  33. 33.

    , , , , , et al. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet 2009; 18: 2099–2114.

  34. 34.

    , , , , , et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000; 25: 306–310.

  35. 35.

    , , , , , et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92–95.

  36. 36.

    , , , , , et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007; 13: 685–687.

  37. 37.

    , , , , , et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 2012; 109: 2132–2137.

  38. 38.

    , , , , , et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010; 19: 2581–2593.

  39. 39.

    , , , , , et al. The RPGRIP1-deficient dog, a promising canine model for gene therapy. Mol Vis 2009; 15: 349–361.

  40. 40.

    , , , , , et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231–2239.

  41. 41.

    , , , , , et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008; 105: 15112–15117.

  42. 42.

    , , , , , et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240–2248.

  43. 43.

    , , , , , et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014; 383: 1129–1137.

  44. 44.

    , , , , , et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet 2015; 24: 3956–3970.

  45. 45.

    , , , , , et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8: 253–261.

  46. 46.

    , , . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224–2232.

  47. 47.

    , , , , , et al. A one-hit model of cell death in inherited neuronal degenerations. Nature 2000; 406: 195–199.

Download references

Acknowledgements

We thank Dr Jeng-Shin Lee at the Research Vector Core at Harvard Medical School for AAV vector packaging, and Drs Peter Colosi and Zhijian Wu at the National Eye Institute for helpful discussions. This work was supported by National Eye Institute grant EY10581, NEI core grant for Vision Research (5P30EY14104), the Foundation Fighting Blindness, the Foundation for Retina Research, the Massachusetts Lions Eye Research Fund and by grants from the European Union (AAVEYE), the UK Department of Health, National Institute of Health Research BMRC for Ophthalmology and UK Fight for Sight.

Author information

Affiliations

  1. Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA

    • B S Pawlyk
    • , M Adamian
    • , E L Berson
    •  & M A Sandberg
  2. National Eye Institute, Bethesda, MA, USA

    • O V Bulgakov
    • , X Sun
    •  & T Li
  3. MRC Human Genetics Unit, University of Edinburgh, Edinburgh, UK

    • X Shu
    •  & A F Wright
  4. Department of Life Sciences, Glasgow Caledonian University, Glasgow, UK

    • X Shu
  5. Department of Genetics, University College London Institute of Ophthalmology, London, UK

    • A J Smith
    •  & R R Ali
  6. Schepens Eye Research Institute, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA

    • S Khani

Authors

  1. Search for B S Pawlyk in:

  2. Search for O V Bulgakov in:

  3. Search for X Sun in:

  4. Search for M Adamian in:

  5. Search for X Shu in:

  6. Search for A J Smith in:

  7. Search for E L Berson in:

  8. Search for R R Ali in:

  9. Search for S Khani in:

  10. Search for A F Wright in:

  11. Search for M A Sandberg in:

  12. Search for T Li in:

Competing interests

RRA and AJS are co-founders of Athena Vision Limited with a commercial interest in gene therapy for X-linked RP. The remaining authors declare no conflict of interest.

Corresponding authors

Correspondence to B S Pawlyk or T Li.

Supplementary information

Image files

  1. 1.

    Supplementary Figure

Word documents

  1. 1.

    Supplementary Methods

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/gt.2015.93

Note added in proof

While this manuscript was under review, the ORF15 cDNA used to treat the canine model of RPGR was found to have undergone multiple deletions and other types of changes, supporting the view that the original 'full-length' RPGR-ORF15 is prone to spontaneous mutations (Deng WT et al. Stability and safety of an AAV vector for treating RPGR-ORF15 X-linked retinitis pigmentosa. Hum Gene Ther 2015; 26: 593-602).

Supplementary Information accompanies this paper on Gene Therapy website (http://www.nature.com/gt)

Further reading